Clinical trial Manifest-2
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (Manifest-2)
| Cancers | |
|---|---|
| Organ | Néoplasme myéloprolifératif (MPN) |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Constellation |
| EudraCT Identifier | 2020-001989-10 |
| Inclusion criteria | Have a confirmed diagnosis of MF ; Require therapy for MF in the opinion of the Investigator and are eligible for treatment with ruxolitinib ; Have DIPSS risk category Intermediate-1 or higher |
| Last update |